Our Team Jonathan Cohen Founder, CEO Jonathan Cohen is the founder, president, and CEO of 20/20 GeneSystems. Under Mr. Cohen’s leadership, 20/20 has brought in approximately $7.5 million in grant funding and launched two successful products, a bio-detection kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for …
Investing with 20/20 Investors Welcome! 20/20 GeneSystems is a U.S. based private corporation located in Maryland. Investment opportunities are currently available and as a Reg A+ company, anyone can become a shareholder in our company. We have raised more than $5 million in equity crowd funding, making us one of the most successful crowd-funding life …
The Future of Cancer Screening 20/20 GeneSystems pioneers innovative bio-testing and cancer diagnostic tools that address compelling unmet needs. 20/20’s digital diagnostics business develops and commercializes A.I. powered cancer screenings tests deliver better tools to improve early detection of the most common cancers globally. Our emergency bio-detection business includes our patented BioCheck which is widely used by emergency responders. …
20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development.
